Abstract:Background: The role of locoregional radiotherapy in patients with primary metastatic nasopharyngeal carcinoma (mNPC) is unclear.Methods: In our open-label, phase 3, multi-centre randomized controlled trial, patients with primary mNPC, staged at IVc at the diagnosis of NPC were enrolled.Key inclusion criteria were CR or PR evaluated by imaging study after three cycles of chemotherapy according to the RECST v1.1; a KPS of at least 70.Eligible patients were randomly assigned in a 1:1 ratio to receive either chemotherapy plus radiotherapy or chemotherapy alone.Chemotherapy regimens were fluorouracil at 5 g/m 2 over 120 h and cisplatin at 100 mg/m 2 on day 1 once every 3 weeks for a maximum of six cycles.The primary endpoint was OS.We did efficacy analyses in ITT population.Safety analyses were done in patients receiving allocated treatment.This study is registered with ClinicalTrials.gov,number NCT02111460, and is ongoing.Results: Between April 2014 and August 2018, 126 eligible patients were randomly assigned to receive chemotherapy plus radiotherapy (n ¼ 63), or chemotherapy alone (n ¼ 63).In August 2018, the randomization was temporarily suspended due to an imbalance in deaths between the two groups and the ad hoc IDMC and the ethics committee of SYSUCC both recommended that the trial be permanently closed to new patient enrollment after IDMC confirmed the previously identified imbalance with this additional follow-up data in February 2019.The median follow-up time for OS was 25.2 months.The median OS was 40.2 months (95%CI 25.7-54.7) in the chemotherapy plus radiotherapy group and 24.5 months (95%CI 15.3-33.7) in the chemotherapy alone (HR 0.45 95% CI 0.25-0.80;P ¼ 0.007).No significant differences between the two treatment groups were observed in terms of hematological toxicity and gastrointestinal reaction.The frequency of grade 2-3 skin reaction and grade 3-4 mucositis in chemotherapy plus radiotherapy was significantly higher than those in chemotherapy alone groups (P < 0.05).Conclusions: Chemotherapy plus radiotherapy significantly improved overall survival in primary metastatic nasopharyngeal carcinoma with acceptable toxicity and tolerability.

Multimodality Treatment May Improve The Survival Rate Of Patients With Metastatic Nasopharyngeal Carcinoma With Good Performance Status

Therapeutic Results of 46 Patients with Initially Diagnosed Metastatic Nasopharyngeal Carcinoma

Combined High-dose Radiation Therapy and Systemic Chemotherapy Improves Survival in Patients with Newly Diagnosed Metastatic Nasopharyngeal Cancer

Retrospective Analysis of 234 Nasopharyngeal Carcinoma Patients with Distant Metastasis at Initial Diagnosis: Therapeutic Approaches and Prognostic Factors

Systemic Chemotherapy and Sequential Locoregional Radiotherapy in Initially Metastatic Nasopharyngeal Carcinoma: Retrospective Analysis with 821 Cases

Locoregional Radiotherapy in Patients with Distant Metastases of Nasopharyngeal Carcinoma at Diagnosis

Survival benefit of radiotherapy for metastatic nasopharyngeal carcinoma: a retrospective analysis based on SEER database

Induction Chemotherapy Combined with Intensity-Modulated Radiotherapy for 129 Nasopharyngeal Carcinoma Patients with Synchronous Metastases: A Retrospective Study

Intensity-modulated Radiotherapy Prolongs the Survival of Patients with Nasopharyngeal Carcinoma Compared with Conventional Two-Dimensional Radiotherapy: A 10-Year Experience with a Large Cohort and Long Follow-Up

Combined CT-guided Radiofrequency Ablation with Systemic Chemotherapy Improves the Survival for Nasopharyngeal Carcinoma with Oligometastasis in Liver: Propensity Score Matching Analysis

Neoadjuvant Chemotherapy And Prognostic Subgroups Defined By Survival Benefit In Patients With Locoregionally Advanced Nasopharyngeal Carcinoma.

1108OChemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial

Chemotherapy plus radiotherapy makes curability a possibility in nasopharyngeal carcinoma patients with distant metastasis at diagnosis

Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Treatment Outcomes of a Prospective, Multicentric Clinical Study

Survival Effects of Radiotherapy on Patients Newly Diagnosed with Distant Metastatic Nasopharyngeal Carcinoma in Non-High-Incidence Areas

Survival Benefit with Palliative Local Radiotherapy in Metastatic Nasopharyngeal Carcinoma

Survival Benefit Of Adding Chemotherapy To Intensity Modulated Radiation In Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Prognostic Analysis of 152 Patients with Distant Metastasis after Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma.

A Study of the Combined Treatment Strategy for Patients with Nasopharyngeal Carcinoma Based on the Analysis of the Treatment Results from 749 Cases

Risk subset of the survival for nasopharyngeal carcinoma patients with bone metastases: who will benefit from combined treatment?

Synchronous Metastatic Nasopharyngeal Carcinoma: Characteristics and Survival of Patients Adding Definitive Nasopharyngeal-Neck Radiotherapy to Systematic Chemotherapy